Coferon
Coferon employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells.
Launch date
Employees
Market cap
-
Enterprise valuation
$48—72m (Dealroom.co estimates Jul 2012.)
Town of Brookhaven New York (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $7.1m | Debt | |
N/A | $3.0m | Early VC | |
N/A | $217k | Debt | |
$12.0m | Series B | ||
N/A | $1.0m | Debt | |
N/A | $4.0m | Debt | |
N/A | $1.0m | Debt | |
Total Funding | $15.0m |
Recent News about Coferon
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.